Covance

covance drug development clinical trials clinical development cro market access services clinical research phase iv drug development drug research clinical studies pharmacovigilance pharmaceutical market access biotechnology patient centricity case study pharma regulatory considerations covance inc. drug development drug studies clinical trial optimization gene therapy biotech regulatory healthcare cell therapy patient recruitment data fda biosimilars preclinical crop protection drug safety patient enrollment fspx risk management drug trials covance inc gene replacement therapies inhalation studies chemical services reach real-world evidence bioanalysis lifesciences labcorp biopharmaceutical analytical solutions rwe phase i drug development pharmaceuticals safety assessment send biomarkers patient safety preclinical development patient insights pharmacovigilance outsourcing patient support mass spectrometry biotech development bio cmc xcellerate solutions medical devices study design nash central laboratory services drug development tools biologics diagnostics development nonclinical development covance fspx cgmp medicine patient access patient voice sciformix marker access pv strategy functional service provider phase ii-iv bioanalytical scientific research clinical trial technology clinical pharmacology clinical trial data antibodies central labs diabetes virtual recruitment china vaccine rare disease pediatrics nonclinical data clinical (phase i - iii) immuno-oncology oncology solutions rheumatoid arthritis clinical testing respiratory clinical development antibiotics covance market access covance labs crop studies covance inc. crop testing pharma case study oral toxicity studies toxic substances control act (tsca) toxicity study echa nanomaterials biomarker precision medicine clinical research unit real-world data patient outcomes small biotech eudravigilance regulatory affairs biosimilar cmc analytical solutions safety & risk management commercialization globalcode clinical data clinical fsp fsp patient care patient focus clinical trial case study stroke research oligonucleotides assays scientific posters contract research organization cmc analytical solutions contract research technology marketplace asset management patients pharmacology evidence site selection data management study renal drug cardiology oncology crowdsourcing inflammatory bowel disease immune mediated inflammatory diseases immunotoxicology biorepository specimen lifecycle management global specimen solutions scientific discovery cdx biobanking genotyping mutational testing gene expression genome analysis genomics device development strategy device development genetic disorders chronic inflammatory diseases cancer biological medicines pv solutions post-approval solutions post-approval services car-t clinical studies medical device development class iii medical device in vitro diagnostic product covnace respiratory treatments inhalation technology lab data management market analysis market approval environmental risk assessment investigator sites clinical trial participation cro technology scientific case study patient centric program cro partnership new product launch patient reimbursement late phase development product value eu regulations environmental protection authority (epa) ecotoxicology bee ecotoxicology studies economic co-operation and development plant cultivation oecd plant metabolism studies risk protection data gap analysis biocide authorization biocides chemical accident prevention chemicals control act (cca) chemical safety act on the registration and evaluation of chemical k-reach k-reach legislation us toxic substances control act (tsca) reform pharmacology studies toxicology services chemical toxicology neonicotinoids european chemicals agency reach regulations new product registration reach requirements phase i hybrid trials hybrid trials pediatric trials pediatric medicines pediatric clinical development toxicity bumblebee acute contact and oral toxicity studies ra treatment small molecule bioa real-time data companion diagnostics diagnostics renal expertise renal studies renal drug development phase iv nash trials vabp trials habp trials phase i manufacturing patient organizations patient journey specialty pharma oracle argus accelerator methodology us epa endocrine disruptors (ed) ed regulatory framework regulatory challenges evaluation registration toxicology post approcal primates rodent inhalation study inhaled pharmaceuticals clinical application dose calculation inhalation study design plant protection products (ppps) agrochemical business field trials agriculture pesticide risk liver disease clinical trial design phosphorodiamidate morpholino oligomer (pmo) oncology development clinical monitoring biostatistics clinical data management renal function sdma microalbuminuria ifcc high sensitive (hs) assay troponin neutrophils inflammatory bowel disease (ibd) calprotectin alanine aminotransferase (alt) aspartate aminotransferase (ast) glutamate dehydrogenase gdlh patient intelligence neurology patient populations diabetes protocol gastroenterology cardiovascular protocol r&d center shanghai drug development china in vitro metabolic drug-drug interactions alzheimer's disease ugt inhibition assays ddi assessment cru emerging biotech nucleeic acid therapy capillary gel electrophoresis critical path opportunity lis fda critical path initiative pharma development f value child safety child-resistant packaging drug packaging healthcare data ispor programmatic outsourcing mdt product development molecule development pv automation adverse event (ae) safety data reporting social media health care professionals hcps pharmacovigilance practices medical literature monitoring (mlm) pharmacovigilance regulations medical communication medical literature international pharmaceutical industry medical affairs india medical communications science european union medication us fda european medicines agency (ema) ema monoclonal antibody pharmacokinetic humira mitra adalimumab clinical trial study design anatomic pathology histology aph assay quality rcts randomized clinical trials cra xcellerate informatics suite clinical informatics biosimilars cmc keytruda client data opdivo focid validation send 3.1 send datasets janssen johnson & johnson data analytics automation validation nonclinical data exchange safety & risk management support chemistry solutions biosimilar strategy manufacturing chemistry specimen tracking biomarker results patient data value proposition development health economic communictions clinical study design analytic methods clinical analytics biosimilar development biosimilar cmc biosimilarity late-stage research observational research wbs testing biological matrices lc-ms/ms cpt31 hiv parkinsons trials parkinson's disease clinically isolated syndrome patient retention ms studies multiple sclerosis neuroscience acute ischemic stroke ais trials ais studies rbm risk based monitoring stroke case study phase ii drug development spinal cord injury spinal cord study drug discovery genotoxins non-dna targets micronucleus assay eemgs carcinogens dna in vitro genotoxicants alzheimers research alzheimers studies alzheimers disease bebpa elisa biotherapeutics biocmc vendor management covance biotech experience clinical trial testing health tech machine learning patient service center clinical trial support patient solutions onlcology integration early clinical development life sciences research r&d clinical trial enrollment drug journey drug testing cmc vaccine development analytical development clinical trial cost quality informatics risk-based monitoring collaboration metid lead optimization testing herg late phase safety interaction compliance drug metabolism drug abuse abuse liability investment digital analysis innovation forecast skin phase iii drug development disease optimization ulcerative colitis regulations imid market entry timeline consideration global new drug drug device startup microbiology new compound niemann-pick disease communication cvmer diabetes & endocrinology stem cells ra cystic fibrosis ibd clinical devleopment infectious disease asset value development models infographic immunology nonclinical pathology general tox non-alcoholic steatohepatitis